News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Drug Company DiObex, Inc. Shutting Down
April 8, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Private Equity Hub -- DiObex Inc., a San Francisco-based drug company focused on metabolic disorders like Type II diabetes, has laid off all its employees and is looking to sell its assets, according to VentureWire.
Twitter
LinkedIn
Facebook
Email
Print
Bankruptcy
MORE ON THIS TOPIC
MASH
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead
May 5, 2026
·
2 min read
·
Tristan Manalac
Earnings
Merck drops early-stage TROP ADC, keeps deal doors open as Keytruda clock ticks
April 30, 2026
·
5 min read
·
Gabrielle Masson
Earnings
With growth curve trending up, Biogen looks to early-stage assets for ‘next generation’
April 29, 2026
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly
April 29, 2026
·
2 min read
·
Gabrielle Masson